Global incidence of malignant pleural mesothelioma (MPM) is on the rise and not expected to peak for another 5-15 years. This is alarming, as survival rates are poor and recurrence after surgical intervention is common. Multimodal treatment is often necessary, and hyperthermic intrathoracic chemotherapy (HITHOC) has been widely used for this purpose. HITHOC is achieved by…